Snowden Capital Advisors LLC Has $515,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Snowden Capital Advisors LLC raised its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 84.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,862 shares of the medical equipment provider’s stock after purchasing an additional 2,227 shares during the period. Snowden Capital Advisors LLC’s holdings in Zimmer Biomet were worth $515,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. CKW Financial Group grew its holdings in Zimmer Biomet by 11.7% during the fourth quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock valued at $101,000 after purchasing an additional 100 shares during the last quarter. Dorsey & Whitney Trust CO LLC grew its holdings in Zimmer Biomet by 2.3% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,594 shares of the medical equipment provider’s stock valued at $485,000 after purchasing an additional 102 shares during the last quarter. M&T Bank Corp grew its holdings in Zimmer Biomet by 0.4% during the fourth quarter. M&T Bank Corp now owns 26,827 shares of the medical equipment provider’s stock valued at $2,834,000 after purchasing an additional 108 shares during the last quarter. MGO One Seven LLC grew its holdings in Zimmer Biomet by 5.1% during the fourth quarter. MGO One Seven LLC now owns 2,254 shares of the medical equipment provider’s stock valued at $238,000 after purchasing an additional 110 shares during the last quarter. Finally, Dakota Wealth Management grew its holdings in Zimmer Biomet by 1.3% during the fourth quarter. Dakota Wealth Management now owns 9,620 shares of the medical equipment provider’s stock valued at $1,016,000 after purchasing an additional 122 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Buying and Selling at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $104.40, for a total transaction of $150,649.20. Following the completion of the transaction, the senior vice president now directly owns 8,768 shares of the company’s stock, valued at approximately $915,379.20. This trade represents a 14.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 1.39% of the company’s stock.

Analysts Set New Price Targets

ZBH has been the topic of several analyst reports. Wells Fargo & Company lowered their price target on Zimmer Biomet from $113.00 to $98.00 and set an “equal weight” rating on the stock in a report on Tuesday, May 6th. Stifel Nicolaus set a $115.00 price objective on Zimmer Biomet and gave the company a “buy” rating in a research report on Tuesday, May 6th. Royal Bank of Canada reduced their price objective on Zimmer Biomet from $125.00 to $112.00 and set an “outperform” rating for the company in a research report on Tuesday, May 6th. JPMorgan Chase & Co. reduced their price objective on Zimmer Biomet from $128.00 to $105.00 and set an “overweight” rating for the company in a research report on Tuesday, May 6th. Finally, Barclays reduced their price objective on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a research report on Monday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $113.45.

Zimmer Biomet Stock Down 0.6%

Shares of ZBH stock opened at $95.21 on Wednesday. The stock has a market cap of $18.84 billion, a P/E ratio of 21.40, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. Zimmer Biomet Holdings, Inc. has a one year low of $89.92 and a one year high of $120.13. The stock has a fifty day moving average price of $102.99 and a 200 day moving average price of $105.68. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.04. The company had revenue of $1.91 billion during the quarter, compared to analysts’ expectations of $1.89 billion. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The business’s revenue was up 1.1% on a year-over-year basis. During the same period last year, the business earned $1.94 earnings per share. Analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st were issued a dividend of $0.24 per share. The ex-dividend date was Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.01%. Zimmer Biomet’s payout ratio is presently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.